Suzhou Zelgen BiopharmaceuticalsLtd Past Earnings Performance
Past criteria checks 0/6
Suzhou Zelgen BiopharmaceuticalsLtd has been growing earnings at an average annual rate of 6.7%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 49.3% per year.
Key information
6.7%
Earnings growth rate
14.5%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 49.3% |
| Return on equity | -17.5% |
| Net Margin | -67.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Suzhou Zelgen BiopharmaceuticalsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 387 | -261 | 263 | 489 |
| 31 Dec 23 | 386 | -279 | 265 | 496 |
| 30 Sep 23 | 387 | -296 | 289 | 440 |
| 30 Jun 23 | 417 | -325 | 308 | 463 |
| 31 Mar 23 | 367 | -395 | 334 | 468 |
| 31 Dec 22 | 302 | -457 | 314 | 498 |
| 30 Sep 22 | 290 | -522 | 295 | 565 |
| 30 Jun 22 | 253 | -521 | 279 | 567 |
| 31 Mar 22 | 234 | -491 | 254 | 547 |
| 31 Dec 21 | 190 | -451 | 220 | 509 |
| 30 Sep 21 | 98 | -384 | 177 | 429 |
| 30 Jun 21 | 70 | -368 | 126 | 382 |
| 31 Mar 21 | 28 | -337 | 98 | 338 |
| 31 Dec 20 | 28 | -319 | 93 | 314 |
| 30 Sep 20 | 28 | -292 | 76 | 284 |
| 30 Jun 20 | 0 | -249 | 70 | 237 |
| 31 Mar 20 | 0 | -354 | 145 | 208 |
| 31 Dec 19 | 0 | -462 | 266 | 184 |
| 30 Sep 19 | 0 | -747 | 564 | 171 |
| 31 Dec 18 | 1 | -440 | 319 | 143 |
| 31 Dec 17 | 0 | -146 | 7 | 159 |
| 31 Dec 16 | 0 | -128 | 74 | 61 |
Quality Earnings: 688266 is currently unprofitable.
Growing Profit Margin: 688266 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688266 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.7% per year.
Accelerating Growth: Unable to compare 688266's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688266 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 688266 has a negative Return on Equity (-17.49%), as it is currently unprofitable.